A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study

Trial Profile

A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2018

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms SAMURAI
  • Sponsors CoLucid Pharmaceuticals; Eli Lilly
  • Most Recent Events

    • 01 Jul 2018 Results of pooled analysis from SAMURAI and SPARTAN assessing the dizziness profile including vertigo after oral lasmiditan for acute treatment of migraine presented at the 60th Annual Scientific Meeting of the American Headache Society
    • 01 Jul 2018 Results of pooled data from SAMURAI and SPARTAN assessing efficacy of the lasmiditan for the treatment of acute migraine, were presented at the 60th Annual Scientific Meeting of the American Headache Society.
    • 25 Jun 2018 According to an Eli Lilly media release, data from this trial will be presented at the American Headache Society (AHS) annual meeting (June-July 2018).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top